Navigation Links
New drug, Vemurafenib, doubles survival of metastatic melanoma patients
Date:3/1/2012

A report published this week in the New England Journal of Medicine shows that the 50 percent of metastatic melanoma patients with a specific genetic mutation benefit from the drug Vemurafenib increasing median survival from about 6 months to 15.9 months. In patients who responded, the drug stopped cancer progression for a median 6.7 months.

"For melanoma patients with a BRAF V600 mutation, this drug is a breakthrough. Not a cure, but a major breakthrough," says Karl Lewis, MD, investigator at the University of Colorado Cancer Center, associate professor at the University of Colorado School of Medicine, and one of the study's authors.

Lewis notes that until about 18 months ago, no drug existed for metastatic melanoma the most dangerous form of skin cancer that was proven to extend survival past that of patients who chose not to treat the disease. The CU Cancer Center is a leading treatment center for metastatic melanoma, and has been instrumental in enrolling patients in trials of this new category of melanoma drugs BRAF inhibitors.

The BRAF mutation is a known oncogene a gene that when mutated causes cancer. Specifically, the BRAF V600 mutation signals a cell to grow without bounds. Vemurafenib is a BRAF inhibitor. The mutation turns cancer on and Vemurafenib turns it off.

And turning off BRAF in the approximately 100,000 patients diagnosed worldwide each year with BRAF-positive metastatic melanoma more than doubles their time of survival.

"Rarely do we see results this dramatic," says Lewis. "This represents a new standard of care for patients with metastatic melanoma harboring a BRAF mutation."


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Page: 1

Related medicine news :

1. DOE laboratories help develop promising new cancer fighting drug, vemurafenib
2. Mental Disorders Linked to Drug, Alcohol Abuse in U.S. Vets
3. New Drug, Pradaxa, May Prevent Second Stroke in Certain Heart Patients
4. Researchers engineer microbes for low-cost production of anti-cancer drug, Taxol
5. Cancer Risk Doubles After Organ Transplant, Study Finds
6. Capacity to diagnose osteoporosis doubles in Armenia
7. ADHD Doubles a Childs Risk of Injury: Study
8. Bone marrow transplant survival more than doubles for young high-risk leukemia patients
9. EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy
10. Sitting for long periods doubles risk of blood clots in the lungs
11. Text message support for smokers doubles quit rates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Seceon , ... threats in real-time, today announced a strategic partnership with TechLab Security, ... other Seceon partners, TechLab Security has become a strategic partner and a value ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... families from two offices in Tyler, has announced the latest beneficiary of their ... Wish Network, a nonprofit organization dedicated to fulfilling the dreams of terminally ill ...
(Date:1/17/2017)... ... ... Year’s resolutions or renew their commitment to better health with the start of a new ... kick off 2017 with better smiles. Dr. Mondavi is offering several promotions for the New ... , A new patient package for just $49, which can help new ...
(Date:1/17/2017)... NJ (PRWEB) , ... January 17, 2017 , ... ... Learning Center and the Montclair State University’s Athletic Training Education program forged a ... University’s Athletic Training Education Program, which is consists of both student members ...
(Date:1/16/2017)... (PRWEB) , ... January 17, 2017 , ... Recently, patients ... in Southwest Michigan, joined other volunteers and organizations in support of the annual Binder ... children and families dressed up in colorful costumes of all designs coming out to ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Jan. 17, 2017  From the company that brought a full ... years ago, comes a new line of companion animal pet first ... leader in equine first aid, has developed two sizes of small ... , Inc. Featuring a small and a large ... and rodeo family, is not a newcomer to working with small ...
(Date:1/17/2017)... Jan 17, 2017 Research and Markets has ... Industry 2016-2020" report to their offering. ... The global fluoropolymer market in the ... period 2016-2020. Global Fluoropolymer Market in the Healthcare ... with inputs from industry experts. The report covers the market landscape ...
(Date:1/17/2017)... 2017 ReportsnReports.com adds "Anaphylaxis - Pipeline ... overview of the Anaphylaxis,s therapeutic pipeline with comprehensive information on ... various stages, therapeutics assessment by drug target, mechanism of action ... latest updates, and featured news and press releases. ... Complete report on ...
Breaking Medicine Technology: